Newsroom
- Mallinckrodt Completes Divestiture of Therakos® Business Dec 02, 2024
- Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting Nov 18, 2024
- Mallinckrodt to Present at Jefferies London Healthcare Conference Nov 14, 2024
- Mallinckrodt announces the 2024 Winner of the Extracorporeal Immunomodulation Award Nov 14, 2024
- Mallinckrodt plc Reports Third Quarter 2024 Financial Results and Raises Full Year Guidance Nov 05, 2024
- Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting Oct 30, 2024
- Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI) at the American College of Gastroenterology (ACG) Annual Meeting Oct 29, 2024
- Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at Kidney Week 2024 Oct 26, 2024
- Mallinckrodt to Report Earnings Results for Third Quarter 2024 Oct 24, 2024
- Mallinckrodt Announces an Expanded Rollout of the INOmax® EVOLVE™ DS Delivery System in U.S. Hospitals Oct 10, 2024
- Mallinckrodt Announces Publication of Human Factors Studies and Arthritis Foundation Ease of Use® Certification of Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector Sep 17, 2024
- THERAKOS™ CELLEX™ Photopheresis System Receives CE Certificate Under the European Union Medical Device Regulation (EU MDR) Sep 03, 2024
- Mallinckrodt plc Reports Second Quarter 2024 Financial Results and Raises Full Year Guidance Aug 06, 2024
- Mallinckrodt Announces Availability of Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector in the U.S. Aug 06, 2024
- Mallinckrodt Reaches Agreement to Sell Therakos® Business to CVC for $925 Million Aug 05, 2024
- Mallinckrodt to Report Earnings Results for Second Quarter 2024 Aug 01, 2024
- Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 European Association for the Study of the Liver (EASL) Congress Jun 05, 2024
- Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 Digestive Disease Week® (DDW) May 18, 2024
- Mallinckrodt plc Reports First Quarter 2024 Financial Results and Reaffirms Full Year Guidance May 09, 2024
- Mallinckrodt Announces 2024 Extracorporeal Immunomodulation Award Apr 14, 2024
- Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides 2024 Guidance Mar 26, 2024
- Mallinckrodt Announces Journal Publication of Real-World Data on Acthar® Gel (repository corticotropin injection) to Treat Symptomatic Sarcoidosis in African American and Non-African American Patients Mar 11, 2024
- Mallinckrodt Announces Appointment of Paul O'Neill as Executive Vice President, Quality & Operations, Specialty Brands Mar 04, 2024
- Mallinckrodt Announces U.S. FDA Approval of Supplemental New Drug Application for Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector Mar 01, 2024
- Mallinckrodt Presents Data on Real-World Outcomes with THERAKOS™ CELLEX™ Photopheresis System Treatment at the 2024 Tandem Meetings Feb 21, 2024
- Mallinckrodt Announces Board of Directors and Leadership Updates Feb 02, 2024
- Mallinckrodt Presents New Data on TERLIVAZ® (terlipressin) for Injection at the Society of Critical Care Medicine (SCCM) 2024 Critical Care Congress Jan 22, 2024
- Mallinckrodt Earns Top Score in Human Rights Campaign Foundation's 2023-2024 Corporate Equality Index Dec 27, 2023
- Mallinckrodt Announces Journal Publication of Economic Evidence for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) Dec 21, 2023
- Mallinckrodt Announces FDA Clearance of the INOmax® EVOLVE™ DS Delivery System and Approval of the INOmax® (nitric oxide) Mini-Cylinder Dec 07, 2023
- Mallinckrodt Completes Financial Restructuring and Irish Examinership Proceedings and Emerges From Chapter 11 Nov 14, 2023
- High Court of Ireland Confirms Mallinckrodt Scheme of Arrangement Nov 10, 2023
- Mallinckrodt to Present Breadth of Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Association for the Study of Liver Diseases (AASLD) 2023 Liver Meeting Nov 08, 2023
- Mallinckrodt plc (in Examinership) Reports Third Quarter 2023 Financial Results Nov 07, 2023
- Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Society of Nephrology (ASN) Kidney Week 2023 Scientific Meeting Nov 01, 2023
- Mallinckrodt Presents Latest Health Economics Data on Acthar® Gel (Repository Corticotropin Injection) at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 Oct 26, 2023
- Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American College of Gastroenterology (ACG) Annual Scientific Meeting Oct 22, 2023
- Mallinckrodt plc (in examinership) Receives U.S. Court Approval for Financial Restructuring Plan Oct 10, 2023
- Mallinckrodt Announces Publication of Two Journal Manuscripts with Clinical and Economic Evidence for Acthar® Gel (Repository Corticotropin Injection) Oct 10, 2023
- Mallinckrodt Receives U.S. Food and Drug Administration Label Update for StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen – dsat) Reducing Xenotransplantation Requirements Sep 06, 2023
- Mallinckrodt Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate Capsules and Launches Product Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD) Aug 31, 2023
- Mallinckrodt Receives Court Approval for "First Day" Motions to Support Ongoing Operations Aug 30, 2023
- Mallinckrodt plc Takes Next Step to Implement Comprehensive Financial Restructuring Plan to Address Long-Term Debt and Opioid Obligations Aug 28, 2023
- Mallinckrodt plc Enters into Restructuring Support Agreement with Key Stakeholders on the Terms of a Prepackaged Financial Restructuring Plan Aug 23, 2023
- Mallinckrodt plc Reports Second Quarter 2023 Financial Results and Reaffirms Full Year Guidance Aug 09, 2023
- Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the European Association for the Study of the Liver (EASL) Congress 2023 Jun 15, 2023
- Mallinckrodt Announces Publication of Real-World Data on the Use of Extracorporeal Photopheresis (ECP) in Heart Transplant Patients Jun 13, 2023
- Mallinckrodt Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) at the American Transplant Congress (ATC) 2023 Jun 01, 2023
- Mallinckrodt plc Reports First Quarter 2023 Financial Results and Reaffirms Full Year Guidance May 09, 2023
- Mallinckrodt Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) at Digestive Disease Week (DDW) 2023 May 08, 2023
- Mallinckrodt Recognized as Industry Innovator at National Organization for Rare Disorders (NORD) 2023 Rare Impact Awards May 05, 2023
- Mallinckrodt to Report Earnings Results for First Quarter 2023 Apr 24, 2023
- Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the National Kidney Foundation (NKF) 2023 Spring Clinical Meeting (SCM) Apr 10, 2023
- Mallinckrodt to Present New Retrospective Data on Effect of Acthar® Gel (Repository Corticotropin Injection) to Reduce Corticosteroid Use and Burden for Advanced Sarcoidosis at the Academy of Managed Care Pharmacy (AMCP) 2023 Annual Meeting Mar 21, 2023
- Mallinckrodt Announces Reimbursement Approval in Japan for the CELLEX® Extracorporeal Photopheresis (ECP) System for the Treatment of Chronic Graft Versus Host Disease (cGvHD) Mar 09, 2023
- Mallinckrodt plc Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides 2023 Guidance Feb 28, 2023
- Mallinckrodt to Present at Cowen's 43rd Annual Health Care Conference Feb 16, 2023
- Mallinckrodt to Report Earnings Results for Fourth Quarter 2022 Feb 08, 2023
- Mallinckrodt Presents New TERLIVAZ® (terlipressin) for Injection Data on Hepatorenal Syndrome (HRS) Reversal at the Society of Critical Care Medicine (SCCM) 2023 Critical Care Congress Jan 22, 2023
- Mallinckrodt Announces Appointment of Dr. Peter Richardson, MRCP, as Chief Scientific Officer Jan 12, 2023
- Mallinckrodt Announces 2022 Advancing Extracorporeal Photopheresis Immunomodulation Investigator Award Nov 16, 2022
- Mallinckrodt plc Reports Third Quarter 2022 Financial Results and Reaffirms Guidance Nov 08, 2022
- Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Association for the Study of Liver Diseases (AASLD) 2022 Liver Meeting Nov 03, 2022
- Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Society of Nephrology (ASN) Kidney Week 2022 Scientific Meeting Nov 01, 2022
- Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American College of Gastroenterology (ACG) Annual Scientific Meeting Oct 24, 2022
- Mallinckrodt Receives Approval to List on NYSE American Oct 24, 2022
- Mallinckrodt to Report Earnings Results for Third Quarter 2022 Oct 18, 2022
- Mallinckrodt Announces Appointment of Susan Silbermann to its Board of Directors Oct 06, 2022
- Mallinckrodt Announces Submission of 510(k) to the U.S. FDA for Inhaled Nitric Oxide Delivery System Sep 28, 2022
- Mallinckrodt Announces Appointment of Lisa French as Chief Commercial Officer Sep 19, 2022
- Mallinckrodt Receives U.S. FDA Approval for Terlivaz® (terlipressin) for injection for the Treatment of Hepatorenal Syndrome (HRS) Sep 14, 2022
- Mallinckrodt plc Provides Update on Executive Committee Aug 17, 2022
- Mallinckrodt Announces Appointment of Karen Ling to Its Board of Directors Aug 17, 2022
- Mallinckrodt plc Reports Second Quarter 2022 Financial Results and Provides 2022 Financial Guidance Aug 11, 2022
- Mallinckrodt to Report Earnings Results for Second Quarter 2022 and Provide Business Update Aug 03, 2022
- Mallinckrodt to Present Data on Terlipressin in Adult Patients with Hepatorenal Syndrome (HRS) at the European Association for the Study of the Liver (EASL) 2022 International Liver Congress Jun 23, 2022
- Mallinckrodt Emerges from Chapter 11 with Strengthened Balance Sheet and Enhanced Financial Flexibility Jun 16, 2022
- Mallinckrodt Announces Resubmission of Terlipressin to the FDA for the Treatment of Hepatorenal Syndrome Jun 13, 2022
- Mallinckrodt Announces Anticipated Chapter 11 Emergence and Provides Update on Trading of New Ordinary Shares Jun 13, 2022
- New Retrospective Data on African Americans with Advanced Symptomatic Sarcoidosis Treated with Acthar® Gel (Repository Corticotropin Injection) Presented at the American Thoracic Society Annual International Conference May 17, 2022
- High Court of Ireland Confirms Mallinckrodt Scheme of Arrangement Apr 27, 2022
- Mallinckrodt Announces Publication of Real-World Data from Retrospective Study on the Investigational Use of Inhaled Nitric Oxide in Hospitalized COVID-19 Patients Apr 13, 2022
- Retrospective Study on Real-World Treatment Patterns and Outcomes of Acthar® Gel (Repository Corticotropin Injection) in Patients with Refractory Rheumatoid Arthritis Published in Drugs in Context Mar 28, 2022
- Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501 Mar 23, 2022
- Mallinckrodt Provides a Regulatory Update on Terlipressin Feb 22, 2022
- Mallinckrodt Plan of Reorganization Confirmed by U.S. Court Feb 03, 2022
- Mallinckrodt Earns Top Marks Again in Human Rights Campaign Foundation's 2022 Corporate Equality Index Jan 31, 2022
- Mallinckrodt Announces Enrollment of First Patient in Phase 1/2a StrataSOMA Clinical Trial of StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat) for Investigating the Treatment of Full-Thickness Burns Dec 16, 2021
- New Data on Patients with Cutaneous T-cell Lymphoma Treated with Extracorporeal Photopheresis from a Retrospective Study Presented at the American Society of Hematology Annual Meeting Dec 13, 2021
- Mallinckrodt Presents Results from Two Retrospective Studies on Real World Characteristics and Outcomes of Patients with Hepatorenal Syndrome Type-1 (HRS-1) at The Liver Meeting Digital Experience Nov 12, 2021
- Mallinckrodt and Terumo Blood and Cell Technologies Announce Positive Recommendations in Australia for Public Funding of UVADEX® (methoxsalen) for ECP Administration with the THERAKOS® CELLEX® Photopheresis System for Chronic Graft Versus Host Disease (cGvHD) in Adults Oct 28, 2021
- Mallinckrodt Presents Results on Real World Treatment Patterns and Outcomes in Hospitalized Patients with Esophageal Variceal Hemorrhage and Liver Cirrhosis Treated with Terlipressin at the American College of Gastroenterology Annual Scientific Meeting Oct 25, 2021
- Mallinckrodt Reaches Settlements with the Official Committee of Opioid Related Creditors, the Official Committee of Unsecured Creditors and Second Lien Noteholders Sep 03, 2021
- Mallinckrodt Presents Interim Results on Real World Use of Extracorporeal Photopheresis (ECP) in Heart Transplant Patients in a Late-Breaking Presentation at the 20th Congress of the European Society for Organ Transplantation (ESOT) Sep 02, 2021
- Mallinckrodt Announces Publication of Phase 3 STRATA2016 Study in Burns Jul 07, 2021
- Mallinckrodt Announces Inclusion of Acthar® Gel (Repository Corticotropin Injection) in New European Respiratory Society (ERS) Treatment Guidelines for Patients with Pulmonary Sarcoidosis Jul 01, 2021
- Mallinckrodt Announces U.S. FDA Approval of StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat) Jun 15, 2021
- Mallinckrodt Presents Data Evaluating Acthar® Gel (Repository Corticotropin Injection) for the Treatment of Severe Keratitis at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting May 03, 2021
- Mallinckrodt Presents Data Evaluating INOmax® (Nitric Oxide) Gas, for Inhalation in a Phase 4 Observational Registry in Neonates with Pulmonary Hypertension at the Pediatric Academic Societies (PAS) 2021 Virtual Meeting Apr 30, 2021
- National Association of Manufacturers Selects Mallinckrodt for Two Prestigious Manufacturing Leadership Awards Mar 29, 2021
- Mallinckrodt Supports Healthcare Businesswomen’s Association as Two Employees Honored with Prominent Awards Mar 24, 2021
- Mallinckrodt Announces U.S. Food and Drug Administration (FDA) Approves Updated Acthar® Gel (Repository Corticotropin Injection) Label Mar 22, 2021
- Mallinckrodt Announces 2021 Advancing Extracorporeal Photopheresis Immunomodulation Investigator Award Mar 19, 2021
- Mallinckrodt Gains Support for Its Restructuring Support Agreement from Lenders Holding Approximately $1.3 Billion of Its First Lien Term Loans Mar 10, 2021
- Mallinckrodt Announces New England Journal of Medicine Publication of Results from its Phase 3 CONFIRM Study of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1) Mar 04, 2021
- Mallinckrodt Provides Regulatory Update on StrataGraft® Feb 12, 2021
- Mallinckrodt Earns Top Marks in Human Rights Campaign’s 2021 Corporate Equality Index Jan 29, 2021
- Mallinckrodt Receives Approval in Japan of the CELLEX® Extracorporeal Photopheresis System for Treatment of Chronic Graft Versus Host Disease Jan 27, 2021
- Mallinckrodt Announces Real World Data on Hepatorenal Syndrome (HRS) and Acute Kidney Injury (AKI) in Patients with Liver Disease at The Liver Meeting Digital Experience Nov 16, 2020
- Mallinckrodt Announces Data from a Multicenter Post Hoc Analysis of Terlipressin in Patients with Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI) at The Liver Meeting Digital Experience Nov 16, 2020
- Mallinckrodt Provides Update on Potential Regulatory Path for Terlipressin in U.S. Nov 13, 2020
- Mallinckrodt Initiates Retrospective Study of the Use of Inhaled Nitric Oxide in COVID-19 Patients Nov 10, 2020
- Mallinckrodt Announces Data at Kidney Week 2020 Reimagined that Showed A Potential for Reduced Need for Renal Replacement (RRT) Therapy for Patients with Hepatorenal Syndrome Type 1 (HRS-1) Treated with Terlipressin Oct 29, 2020
- Mallinckrodt Receives Court Approval of "First Day" Motions to Support Business Operations Oct 14, 2020
- Mallinckrodt Secures Broad Consensus with Key Stakeholders on Comprehensive Chapter 11 Restructuring Oct 12, 2020
- Mallinckrodt Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for Terlipressin for the Treatment of Hepatorenal Syndrome Type 1 (HRS-1) Sep 14, 2020
- Mallinckrodt Announces 2020 Investigator Award to Further Advances in ECP Immunomodulation Aug 31, 2020
- Mallinckrodt's Hobart, N.Y. Site Recognized With Two Manufacturing Leadership Awards Aug 24, 2020
- Mallinckrodt Announces U.S. FDA Filing Acceptance of Biologics License Application for StrataGraft® Regenerative Skin Tissue for Treatment of Adults with Deep Partial-thickness Thermal Burns Aug 10, 2020
- Mallinckrodt plc Reports Earnings for the Second Quarter 2020 and Highlights Pipeline Advancements Aug 04, 2020
- Mallinckrodt Announces U.S. Food and Drug Administration (FDA) Advisory Committee Voted to Recommend Terlipressin for Approval to Treat Patients with Hepatorenal Syndrome Type 1 (HRS-1) Jul 15, 2020
- Mallinckrodt and Terumo BCT Announce Positive Recommendations in Australia for Public Funding of UVADEX® (methoxsalen) for ECP Administration with the THERAKOS® CELLEX® Photopheresis System for Treatment of Cutaneous T-Cell Lymphoma (CTCL) in Adults Jul 12, 2020
- Mallinckrodt to Report Earnings Results for Second Quarter 2020 Jul 09, 2020
- Mallinckrodt Confirms that U.S. Food and Drug Administration (FDA) Will Convene an Advisory Committee to Review Terlipressin for the Treatment of Patients with Hepatorenal Syndrome Type 1 (HRS-1) Jul 07, 2020
- Mallinckrodt to Present at the BMO Prescriptions for Success Healthcare Conference Jun 17, 2020
- Mallinckrodt to Proceed with Appeal Despite Appellate Court Decision Denying Temporary Injunction in Ongoing Acthar Gel Medicaid Drug Rebate Dispute with the Centers for Medicare and Medicaid Services (CMS) Jun 15, 2020
- Mallinckrodt to Present Phase 3 StrataGraft® Regenerative Skin Tissue Clinical Trial Results on Severe Burns During the Virtual American Burn Association 52nd Annual Meeting Jun 15, 2020
- Real-World Data of Terlipressin in Hospitalized Patients in U.K. with Hepatorenal Syndrome Type 1 (HRS-1) Published in Alimentary Pharmacology and Therapeutics Jun 11, 2020
- Mallinckrodt Completes Rolling Submission of Biologics License Application for StrataGraft® Regenerative Skin Tissue to U.S. Food and Drug Administration Jun 09, 2020
- Mallinckrodt Will Appeal District Court Ruling in Case Involving Ongoing Acthar Medicaid Drug Rebate Dispute with the Centers for Medicare and Medicaid Services (CMS) Jun 01, 2020
- Mallinckrodt plc Reports Earnings for the First Quarter 2020 and Highlights Pipeline Progress May 05, 2020
- Mallinckrodt Announces Positive Findings in INOmax® (Nitric Oxide) Gas, for Inhalation Phase 4 Observational Registry in Neonates with Pulmonary Hypertension; Ends Trial Early May 04, 2020
- Mallinckrodt Supports Investigator-Initiated Study at Massachusetts General Hospital to Assess Effectiveness of Inhaled Nitric Oxide in Patients with Severe Acute Respiratory Distress Syndrome Due to COVID-19 Apr 30, 2020
- Mallinckrodt Announces U.S. Food and Drug Administration (FDA) Filing Acceptance of New Drug Application for Terlipressin for Treatment of Hepatorenal Syndrome Type 1 (HRS-1) Apr 22, 2020
- Mallinckrodt to Report Earnings Results for First Quarter 2020 Apr 16, 2020
- Mallinckrodt Announces Publication of Data on Acthar® Gel (Repository Corticotropin Injection) from its Randomized, Double-Blind, Placebo-Controlled Phase 4 Study in Rheumatoid Arthritis (RA) in Rheumatology and Therapy Apr 15, 2020
- Mallinckrodt Initiates Rolling Submission of Biologics License Application for StrataGraft® Regenerative Skin Tissue to U.S. Food and Drug Administration Apr 06, 2020
- Mallinckrodt and Novoteris Receive Clearance from Health Canada to Start Pilot Trial of High-Dose Inhaled Nitric Oxide Therapy for COVID-19 Infection and Associated Lung Complications Apr 01, 2020
- Mallinckrodt Pharmaceuticals Statement Regarding Product Supply Mar 20, 2020
- Mallinckrodt Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration (FDA) for Terlipressin for the Treatment of Patients with Hepatorenal Syndrome Type 1 (HRS-1) Mar 17, 2020
- Mallinckrodt Confirms Court Decision in Lawsuit Against U.S. Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) and Provides Update Related to Global Opioid Settlement and Present Financing Activities Mar 16, 2020
- Mallinckrodt Evaluates the Potential Role for Inhaled Nitric Oxide to Treat COVID-19 Associated Lung Complications, Engages with Scientific, Governmental and Regulatory Agencies Mar 12, 2020
- Mallinckrodt Provides Update on Proposed Global Opioid Settlement Mar 11, 2020
- Data on Acthar® Gel (Repository Corticotropin Injection) Therapy in Immunoglobulin A Nephropathy (IgAN) Published in Kidney International Reports Mar 05, 2020
- Mallinckrodt Announces Publication of New Data on Acthar® Gel (Repository Corticotropin Injection) in Rheumatoid Arthritis, Systemic Lupus Erythematosus and Dermatomyositis/Polymyositis Published in Open Access Rheumatology: Research and Reviews Mar 04, 2020
- Mallinckrodt Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration (FDA) for Terlipressin for the Treatment of Patients with Hepatorenal Syndrome Type 1 (HRS-1) Mar 02, 2020
- Mallinckrodt to Present New Data from two Studies on Acthar® Gel (Repository Corticotropin Injection) Therapy in Multiple Sclerosis (MS) Relapse at Fifth Annual ACTRIMS Forum 2020 Feb 27, 2020
- Mallinckrodt plc Reports Strong Fourth Quarter and 2019 Results Feb 25, 2020
- Mallinckrodt Announces Agreement in Principle for Global Opioid Settlement and Associated Debt Refinancing Activities Feb 25, 2020
- Mallinckrodt to Report Earnings Results for Fourth Quarter and Fiscal 2019 Feb 14, 2020
- Mallinckrodt Recognized as one of the "2020 Best Places to Work for LGBTQ Equality" Jan 30, 2020
- Mallinckrodt to Present at the 38th Annual J.P. Morgan Healthcare Conference Dec 23, 2019
- First Patient Enrolled in Mallinckrodt Phase 4 Trial of Acthar® Gel (Repository Corticotropin Injection) for Severe Keratitis Dec 16, 2019
- Mallinckrodt Announces Plans to Update Its Incentive Compensation Clawback Policy and Create Opioid Report Dec 10, 2019
- Mallinckrodt Presents Data on a Novel Predictive Model to Identify Infants at Risk for Infantile Spasms (IS) at the 2019 Annual Meeting of the American Epilepsy Society (AES) Dec 07, 2019
- Mallinckrodt plc Announces Final Results of Exchange Transactions Dec 05, 2019
- Mallinckrodt Moves Date and Time of Its Fireside Chat at Piper Jaffray Annual Healthcare Conference Dec 02, 2019
- Data on Acthar® Gel (Repository Corticotropin Injection) Therapy in Symptomatic Sarcoidosis Published in Therapeutic Advances in Respiratory Disease Nov 26, 2019
- Mallinckrodt plc Announces Early Results of Exchange Transactions Nov 19, 2019
- Mallinckrodt to Present at Piper Jaffray Annual Healthcare Conference Nov 19, 2019
- Mallinckrodt Announces New Clinical Data Evaluating Acthar® Gel (Repository Corticotropin Injection) in Rheumatoid Arthritis (RA) at the 2019 American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting Nov 12, 2019
- Mallinckrodt Presents Positive Phase 3 Results from its CONFIRM Study of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1) at The Liver Meeting® 2019 Nov 11, 2019
- Mallinckrodt to Present at Jefferies London Healthcare Conference Nov 08, 2019
- Mallinckrodt Announces Data Publication on the Treatment Effectiveness of Acthar® Gel (Repository Corticotropin Injection) for Resolution of Multiple Sclerosis Relapse in a U.S. Health Plan Population Nov 07, 2019
- Mallinckrodt plc Announces Exchange Offers and Consent Solicitations Nov 05, 2019
- Mallinckrodt plc Reports Earnings and Pipeline Advancements for the Third Quarter 2019 and Raises Adjusted Diluted Earnings Per Share Guidance Range for 2019 Nov 05, 2019
- Mallinckrodt Completes Sale of BioVectra Inc. for up to $250 Million Nov 04, 2019
- Mallinckrodt Announces UVADEX® (Methoxsalen) Approved in Australia for use with the THERAKOS® CELLEX® Photopheresis System for Treatment of Chronic Graft Versus Host Disease (cGvHD) and Skin Manifestations of Cutaneous T-Cell Lymphoma (CTCL) in Adults Oct 31, 2019
- Mallinckrodt Announces Launch of 2020 Award in Support of Advancing ECP Immunomodulation Oct 22, 2019
- Mallinckrodt Raises Awareness of Critical Role Respiratory Therapists Play in Patient Care During Respiratory Care Week Oct 21, 2019
- Mallinckrodt to Present Results from its Pivotal Phase 3 CONFIRM Study of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1) at The Liver Meeting® 2019 Oct 21, 2019
- Mallinckrodt to Report Earnings Results for Third Quarter 2019 Oct 09, 2019
- Mallinckrodt Announces Positive Top-Line Findings from its Observational Registry Assessing Relapse Recovery in Multiple Sclerosis Relapse Patients Treated with Acthar® Gel (Repository Corticotropin Injection) Oct 01, 2019
- Mallinckrodt Finalizes Settlement to Resolve "Track 1" Opioid Cases with the Ohio Counties of Cuyahoga and Summit Sep 30, 2019
- Mallinckrodt Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of StrataGraft® Regenerative Tissue in Patients with Deep Partial-thickness Thermal Burns Sep 23, 2019
- Mallinckrodt to Present at Cantor Global Healthcare Conference Sep 20, 2019
- Mallinckrodt Analysis Suggests Acthar® Gel (Repository Corticotropin Injection) May be a Cost-Effective Option Compared to Other Late-Line, Adult Treatments for Multiple Sclerosis Relapse Sep 13, 2019
- Mallinckrodt Agrees to Sell BioVectra Inc. to H.I.G. Capital for $250 Million Sep 10, 2019
- Mallinckrodt Announces Settlement in Principle to Resolve "Track 1" Opioid Cases with the Ohio Counties of Cuyahoga and Summit Sep 06, 2019
- Mallinckrodt Announces Completion of Previously Disclosed Settlement Agreement with U.S. Department of Justice on Legacy Questcor Sales and Marketing Activities Sep 03, 2019
- Mallinckrodt Comments on U.S. Court of Appeals Ruling in Patent Infringement Lawsuit against Praxair, Inc. Aug 27, 2019
- Mallinckrodt to Present at Morgan Stanley 17th Annual Global Healthcare Conference Aug 21, 2019
- Mallinckrodt Announces Positive Top-Line Results from its Pivotal Phase 3 CONFIRM Trial of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1) Aug 15, 2019
- Mallinckrodt Announces Publication of Results of Phase 1b Clinical Trial of StrataGraft® Regenerative Tissue in Burns Aug 13, 2019
- First Patient Enrolled in Mallinckrodt's Phase 2a Study of Investigational Drug MNK-6106 in Hepatic Cirrhosis and Chronic Hepatic Encephalopathy (HE) Aug 12, 2019
- Mallinckrodt plc Reports Strong Results in Second Quarter 2019, Raises Adjusted EPS Guidance for 2019, and Announces Suspension of Specialty Generics Spin-off Aug 06, 2019
- Mallinckrodt to Present at Wells Fargo Securities 2019 Healthcare Conference Aug 02, 2019
- Mallinckrodt To Make An Equity Investment In Silence Therapeutics As Part Of A Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases Jul 18, 2019
- Mallinckrodt And Silence Therapeutics Announce Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases Jul 18, 2019
- Mallinckrodt Halts Phase 2B Trial Investigating the Use of Acthar® Gel (Repository Corticotropin Injection) in Amyotrophic Lateral Sclerosis (ALS) Jul 16, 2019
- Mallinckrodt to Report Earnings Results for Second Quarter 2019 Jul 01, 2019
- Mallinckrodt Achieves 50 Percent Enrollment for Phase 2B Trial Investigating the Use of Acthar® Gel (Repository Corticotropin Injection) in Amyotrophic Lateral Sclerosis (ALS) Jun 24, 2019
- All Primary and Secondary Outcome Targets Met in Mallinckrodt's Phase 4 Acthar® Gel (Repository Corticotropin Injection) Rheumatoid Arthritis (RA) Clinical Trial (n=259) with Data Presented at the European Congress of Rheumatology 2019 (EULAR) Jun 13, 2019
- Mallinckrodt to Present at BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference Jun 11, 2019
- Mallinckrodt Announces Agreement In Principle With U.S. Department Of Justice On Legacy Questcor Sales And Marketing Activities; Responds To Government Civil Litigation Involving Legacy Questcor Charitable Foundation Activities Jun 05, 2019
- Mallinckrodt Pharmaceuticals Data Presented at Annual Scientific Conference Jun 03, 2019
- Mallinckrodt to Present at Raymond James Life Sciences and Medtech Conference May 31, 2019
- Mallinckrodt Announces Positive Open-Label Results from Phase 4 Acthar® Gel (Repository Corticotropin Injection) Clinical Trial in Rheumatoid Arthritis (RA) to be Presented at the European Congress of Rheumatology 2019 (EULAR) May 29, 2019
- Mallinckrodt Updates Plans for Company Separation and Spin-Off of Specialty Generics Business to Shareholders May 28, 2019
- Mallinckrodt Announces Election of Carlos V. Paya, M.D., Ph.D. to its Board of Directors May 21, 2019
- Mallinckrodt Files Suit against U.S. Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) to Protect Medicaid Patient Access to Acthar® Gel May 21, 2019
- Mallinckrodt Responds to Anticipated Questions Related to its Suit Against the U.S. Department of Health and Human Services and the Centers for Medicare and Medicaid Services (CMS, the Agency) May 21, 2019
- Mallinckrodt Completes Enrollment of Phase 3 Terlipressin CONFIRM Trial May 14, 2019
- Mallinckrodt plc Reports Strong Growth in First Quarter 2019 Results, Raises Guidance for 2019, and Continues to Make Significant Advancements in Pipeline and Data Generation May 07, 2019
- Cancer Prevention Pharmaceuticals (CPP) and Mallinckrodt Announce Results from Pivotal Phase 3 Trial of CPP-1X/Sulindac in Patients with Familial Adenomatous Polyposis May 07, 2019
- Mallinckrodt Announces Encouraging Interim Analysis Results in Phase 4 Registry of INOmax® (Nitric Oxide) Gas for Inhalation for Pulmonary Hypertension in Neonates May 06, 2019
- Mallinckrodt to Present Open-Label Results from Phase 4 Acthar® Gel (Repository Corticotropin Injection) Clinical Trial in Patients with Rheumatoid Arthritis at Annual European Congress of Rheumatology (EULAR 2019) May 02, 2019
- Mallinckrodt States its Position on Legacy Acthar® Gel Legal Matter Apr 30, 2019
- Mallinckrodt Completes Expansion of Operations and Manufacturing Facility for StrataGraft® Regenerative Skin Tissue in Madison, Wis. Apr 24, 2019
- Mallinckrodt Lupus Phase 4 Clinical Study for Acthar® Gel (Repository Corticotropin Injection) Completes Enrollment in Difficult-to-Manage Population Apr 23, 2019
- Mallinckrodt Reports Top-Line Results from Proof-of-Concept Study of Nitric Oxide Gas in Ex-Vivo System of Human Lung Transplants Apr 18, 2019
- Data on Impact of Revised Consensus Recommendations on Time to Treatment and Serum Creatinine (SCr) at Treatment Start for Patients with Hepatorenal Syndrome Type 1 (HRS-1) Presented at the 2019 International Liver Congress™ (EASL) Apr 15, 2019
- Mallinckrodt Completes Full Enrollment of its Phase 3 Clinical Trial for StrataGraft® Regenerative Skin Tissue Apr 12, 2019
- Mallinckrodt and Washington University St. Louis Select First Collaborative Research Endeavor Apr 11, 2019
- Mallinckrodt's INOmax™ (Nitric Oxide) Gas, for Inhalation, Approved in Australia for Pulmonary Hypertension in Adults in Conjunction with Cardiovascular Surgery Apr 10, 2019
- Data Published on Acthar® Gel (repository corticotropin injection) Disease Status and Utilization Patterns in Uveitis Patients in Journal of Ocular Pharmacology and Therapeutics Apr 09, 2019
- Mallinckrodt Announces Study Demonstrating Effectiveness of ECP Immunomodulation, as an adjunct to local standard therapy, in Treatment of Lung Transplant Patients with Bronchiolitis Obliterans Syndrome (BOS) Apr 05, 2019
- Mallinckrodt Achieves Top Score in 2019 Corporate Equality Index for Third Year in a Row, Recognized as a Best Place to Work for LGBTQ Equality Mar 28, 2019
- Mallinckrodt plc To Report Earnings Results For First Quarter 2019 Mar 27, 2019
- Mallinckrodt Announces 2019 Investigator Award for Pioneering Efforts in ECP Immunomodulation Mar 26, 2019
- Bryan Reasons Joins Mallinckrodt as the Company's Chief Financial Officer (CFO) Mar 18, 2019
- Mallinckrodt's Hobart, N.Y. and St. Louis, Mo. Sites Recognized as 2019 Manufacturing Leadership Award Winners Mar 15, 2019
- Mallinckrodt Presents New Data on Real-World Resource Utilization Associated with Continuation of Systemic Treatment among Patients with Cutaneous T-cell Lymphoma at 2019 American Academy of Dermatology Annual Meeting Mar 04, 2019
- Mallinckrodt plc Reports Strong Fourth Quarter and Total Company 2018 Results, Announces 2019 Guidance and Strategic Priorities Feb 26, 2019
- Mallinckrodt Announces Extracorporeal Photopheresis Research Collaboration Agreement With Transimmune AG Feb 25, 2019
- Mallinckrodt Announces Interim Analysis Results for Therakos® Platform Phase 3 Clinical Trial in Treatment of Pediatric Patients with Steroid Refractory Acute Graft-versus-Host Disease Feb 20, 2019
- Mallinckrodt To Present At Barclays Global Healthcare Conference Feb 12, 2019
- Mallinckrodt Provides Update on Phase 4 Data H.P. Acthar® Gel (Repository Corticotropin Injection) Clinical Trial in Patients with Rheumatoid Arthritis (RA) Feb 05, 2019
- Mallinckrodt Will Respond to U.S. House Committee on Oversight and Reform Request for Information on H.P. Acthar® Gel Jan 14, 2019
- Mallinckrodt plc To Report Earnings Results For Fourth Quarter And Fiscal 2018 Jan 14, 2019
- Data on Use of Mallinckrodt's H.P. Acthar® Gel (Repository Corticotropin Injection) in Patients with Rare Cause of Nephrotic Syndrome Published in Transplantation Jan 03, 2019
- Mallinckrodt And NPXe Announce First Patient Enrolled In Phase 3 Trial Of Inhaled Xenon Gas Therapy Dec 21, 2018
- Mallinckrodt To Present At 37th Annual J.P. Morgan Healthcare Conference Dec 17, 2018
- Mallinckrodt's SpecGx LLC Receives FDA Complete Response Letter for Abuse-Deterrent, Immediate-Release Reformulation of Roxicodone® (Oxycodone Hydrochloride) Dec 12, 2018
- Mallinckrodt Plans Spin-Off of Specialty Generics Business to Shareholders Dec 06, 2018
- Important Facts About H.P. Acthar® Gel Nov 27, 2018
- Important Facts About H.P. Acthar® Gel Nov 27, 2018
- Mallinckrodt's SpecGx LLC Reports on Outcome of FDA Joint Advisory Committee on Abuse-Deterrent, Immediate-Release Reformulation of Roxicodone® (Oxycodone Hydrochloride) Nov 14, 2018
- Mallinckrodt To Present At BMO Prescriptions For Success Healthcare Conference Nov 12, 2018
- Mallinckrodt Presents Terlipressin Clinical Data at The Liver Meeting® 2018 Nov 09, 2018
- Mallinckrodt Earns International Standard ISO 13485:2016 and Medical Device Single Audit Program (MDSAP) Certifications for INOmax® DSIR® Plus Nitric Oxide Delivery Systems Nov 08, 2018
- Mallinckrodt plc Reports Third Quarter 2018 Results and Raises Earnings Guidance for 2018 Nov 06, 2018
- Leading Hepatorenal Expert Joins Mallinckrodt's Scientific Advisory Council Nov 02, 2018
- First Patient Screened in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis Oct 26, 2018
- Mallinckrodt and the Lupus Foundation of America Present Data from Survey of Over 1,500 Individuals with Self-Reported Lupus at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting Oct 23, 2018
- Mallinckrodt Presents Data on H.P. Acthar® Gel (Repository Corticotropin Injection) in Rheumatoid Arthritis (RA) at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting Oct 22, 2018
- Mallinckrodt To Present At Jefferies London Healthcare Conference Oct 16, 2018
- Mallinckrodt's Stratatech Company Awarded $26 Million in Additional BARDA Funding for Pediatric Studies of StrataGraft® Skin Tissue in Thermal Burns Oct 15, 2018
- U.S. FDA Announces Joint Advisory Committee Review of Mallinckrodt's Abuse-Deterrent, Immediate-Release Reformulation of Roxicodone® (Oxycodone Hydrochloride) Oct 08, 2018
- Mallinckrodt Responds to CBS’ 60 Minutes Segment Sep 30, 2018
- Mallinckrodt plc To Report Earnings Results For Third Quarter Of Fiscal 2018 Sep 25, 2018
- Mallinckrodt Announces Donation of Two Transport Vehicles to Coolmine Therapeutic Community (TC) Sep 17, 2018
- Mallinckrodt To Present At Cantor Global Healthcare Conference Sep 04, 2018
- Mallinckrodt And NPXe Announce FDA Fast Track Designation For Phase 3 Trial Of Inhaled Xenon Gas Therapy Aug 23, 2018
- Mallinckrodt Confirms Receipt of Stannsoporfin Complete Response Letter Aug 22, 2018
- Mallinckrodt To Present At Wells Fargo Securities 2018 Healthcare Conference Aug 10, 2018
- New Mallinckrodt Data Analysis Shows Limited Use Of Opioid-Free Analgesia, Underutilization In Some Patients More Prone To Opioid-Related Adverse Events Aug 09, 2018
- Mallinckrodt plc Reports Second Quarter 2018 Results and Raises Guidance for 2018 Aug 07, 2018
- Mallinckrodt Forms Collaborative Research Partnership with Washington University in St. Louis Aug 06, 2018
- First Patient Enrolled in Mallinckrodt's Phase 2 Duchenne Muscular Dystrophy Trial Aug 02, 2018
- Mallinckrodt Initiates Proof-of-Concept Study of Nitric Oxide Gas in Ex-Vivo System of Human Lung Transplants Aug 01, 2018
- New Health Economic Data on Mallinckrodt's OFIRMEV® (Acetaminophen) Injection Published in Journal of Knee Surgery Jul 09, 2018
- Mallinckrodt Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar® Gel (Repository Corticotropin Injection) Achieves its Enrollment Target Jun 28, 2018
- Mallinckrodt plc To Report Earnings Results For Second Quarter Of Fiscal 2018 Jun 22, 2018
- Mallinckrodt plc To Report Earnings Results For Second Quarter Of Fiscal 2018 Jun 22, 2018
- Mallinckrodt Launches Scientific Advisory Council Jun 21, 2018
- Mallinckrodt Launches Scientific Advisory Council Jun 21, 2018
- Mallinckrodt Reports Interim Findings Of H.P. Acthar® Gel (Repository Corticotropin Injection) Studies Jun 18, 2018
- Mallinckrodt Presents Preliminary Interim Findings of Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar® Gel (Repository Corticotropin Injection) Jun 16, 2018
- Mallinckrodt Presents Interim Findings of Multiple Sclerosis Relapse Registry for H.P. Acthar® Gel Jun 01, 2018
- Mallinckrodt To Present At Goldman Sachs 39th Annual Global Healthcare Conference May 14, 2018
- Mallinckrodt plc Reports First Quarter 2018 Results May 08, 2018
- Mallinckrodt Provides Facts on H.P. Acthar® Gel May 07, 2018
- Mallinckrodt Reports on FDA Joint Advisory Committee Meeting for Stannsoporfin for the Treatment of Newborns at Risk of Developing Severe Jaundice May 03, 2018
- FDA Responds to Mallinckrodt’s Supplemental New Drug Application for New Indication for AMITIZA® (Lubiprostone) Apr 30, 2018
- Mallinckrodt To Present At UBS Global Healthcare Conference Apr 20, 2018
- Mallinckrodt plc Announces $300 Million Debt Repayment Apr 16, 2018
- Mallinckrodt To Present At Deutsche Bank's 43rd Annual Healthcare Conference Apr 09, 2018
- Mallinckrodt Names Paul R. Carter, Anne C. Whitaker to its Board of Directors Apr 04, 2018
- Angus Russell to Succeed Melvin Booth as Mallinckrodt Chairman of the Board in May 2018 Apr 04, 2018
- MNK H.P. Acthar Gel CHART Trial Results Alert Mar 28, 2018
- Mallinckrodt plc To Report Earnings Results For The First Quarter Of Fiscal 2018 Mar 28, 2018
- Mallinckrodt Announces First Investigator Award for Pioneering Efforts in ECP Immunomodulation Mar 20, 2018
- Mallinckrodt Completes Sale Of RECOTHROM® And PREVELEAK® To Baxter Mar 19, 2018
- Mallinckrodt Recognized as Manufacturing Leadership Awards 2018 Winner Mar 15, 2018
- Mallinckrodt plc Reports Fourth Quarter and Fiscal 2017 Results, Announces 2018 Guidance and Sets 2018 Strategic Priorities Feb 27, 2018
- Mallinckrodt Receives FDA Acceptance of Stannsoporfin New Drug Application Filing Feb 23, 2018
- Mallinckrodt Earns Somerset County Planning Board Land Development Honor Feb 21, 2018
- Mallinckrodt To Present At Barclays Global Healthcare Conference Feb 15, 2018
- Mallinckrodt Enrolls First Patient in Phase 1 Study of ExpressGraft™C9T1 Skin Tissue Feb 14, 2018
- Mallinckrodt Completes Acquisition Of Sucampo Pharmaceuticals, Inc. Feb 13, 2018
- Mallinckrodt To Present At Raymond James 39th Annual Institutional Investors Conference Feb 06, 2018
- Mark Casey Joins Mallinckrodt as General Counsel Feb 01, 2018
- First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Pulmonary Sarcoidosis Jan 30, 2018
- Mallinckrodt Will Sell RECOTHROM® And PREVELEAK® To Baxter Jan 08, 2018
- Mallinckrodt Completes Stannsoporfin New Drug Application Filing Jan 04, 2018
- Mallinckrodt To Acquire Sucampo Pharmaceuticals For Approximately $1.2 Billion Dec 26, 2017
- Mallinckrodt plc to Report Fourth Quarter and Full-Year 2017 Earnings Results on Feb. 27, 2018 Dec 19, 2017
- Mallinckrodt Completes Acquisition of Ocera Therapeutics and OCR-002, Its Proprietary Therapy in Development for Treatment of Hepatic Encephalopathy Dec 11, 2017
- Mallinckrodt To Present At 36th Annual J.P. Morgan Healthcare Conference Dec 08, 2017
- Mallinckrodt plc Presents Health Economic Data on Management of Infantile Spasms at American Epilepsy Society Annual Meeting Dec 04, 2017
- Mallinckrodt plc Presents Health Economic Data on OFIRMEV® (acetaminophen) Injection at ASRA 16th Annual Pain Medicine Meeting Nov 16, 2017
- Mallinckrodt To Present At The BMO Prescriptions for Success Healthcare Conference Nov 14, 2017
- Mallinckrodt Earns Top Marks in 2018 Corporate Equality Index, Recognized as a Best Place to Work for LGBTQ Equality Nov 09, 2017
- Mallinckrodt plc Reports Earnings Results for Third Quarter of Fiscal 2017 Nov 07, 2017
- Mallinckrodt To Acquire Ocera Therapeutics And OCR-002, Its Proprietary Therapy In Development For Treatment Of Hepatic Encephalopathy Nov 02, 2017
- Patient Survey Studies Find Multiple Sclerosis Relapse is Underreported; Approximately Half of Patients Do Not Always Engage with Healthcare Practitioners During Relapse Oct 27, 2017
- Mallinckrodt plc Presents Multiple Sclerosis (MS) Relapse Data at 7th Joint ECTRIMS-ACTRIMS Meeting (MSParis2017) Oct 26, 2017
- Mallinckrodt Presents Health Economic Data Related to Hepatorenal Syndrome at The Liver Meeting® 2017, the Annual Meeting of the American Association for the Study of Liver Diseases Oct 23, 2017
- Mallinckrodt Statement on October 20, 2017, Neurology Today Journal Article Oct 20, 2017
- Mallinckrodt To Present At The Stifel 2017 Healthcare Conference Oct 18, 2017
- Mallinckrodt Opens Specialty Brands Office In New Jersey, Announces $100,000 Donation To Princeton University Program For High Achieving, Low-Income High School Students Oct 16, 2017
- Mallinckrodt Continues to Refute Inaccuracies Surrounding its Financial Liabilities Oct 12, 2017
- Mallinckrodt plc to Report Earnings Results for Third Quarter of Fiscal 2017 Oct 10, 2017
- Mallinckrodt Statement on October 7, 2017, CHEST® Journal Article Oct 09, 2017
- Mallinckrodt Will Conduct Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Symptomatic Sarcoidosis Oct 09, 2017
- Mallinckrodt plc Discusses Pipeline Transformation, Company Outlook at Investor Briefing Oct 04, 2017
- Mallinckrodt Licenses Inhaled Xenon Gas Therapy Development Product Oct 02, 2017
- Mallinckrodt Completes Acquisition of InfaCare Pharmaceutical Corporation and Stannsoporfin, its Proprietary Therapy in Late-Stage Development for Newborns at Risk for Severe Jaundice Sep 25, 2017
- Mallinckrodt Advocates for Comprehensive, Multi-Prong Action Plan to Fight Opioid Abuse and Misuse in the United States Sep 22, 2017
- Mallinckrodt Announces Election Of David Norton To Its Board Of Directors Sep 20, 2017
- Open Letter to Mallinckrodt Employees, Customers and Patients Reinforcing Important Facts Related to H.P. Acthar Gel and Other Matters Sep 12, 2017
- Mallinckrodt Statement on Praxair Patent Infringement Ruling Sep 05, 2017
- Mallinckrodt Statement on Missouri Attorney General Investigation Aug 30, 2017
- Mallinckrodt To Present At Morgan Stanley 15th Annual Global Healthcare Conference Aug 15, 2017
- Mallinckrodt plc Reports Earnings Results for Second Quarter of Fiscal 2017 Aug 08, 2017
- Mallinckrodt Statement On Lawsuit Filed By Multnomah County, Oregon, Related To Opioid Products Aug 07, 2017
- Mallinckrodt To Present At Wells Fargo Securities 2017 Healthcare Conference Aug 07, 2017
- Mallinckrodt To Acquire InfaCare Pharmaceutical Corporation And Stannsoporfin, Its Proprietary Therapy In Late-Stage Development For Treatment Of Newborns At Risk For Developing Severe Jaundice Aug 04, 2017
- Mallinckrodt Statement on U.S. DOJ Subpoena Related to Opioid Products Aug 02, 2017
- Mallinckrodt Enrolls First Patient In Phase 4 Registry Of INOMAX® (Nitric Oxide) Gas For Inhalation For Pulmonary Hypertension In Neonates Aug 01, 2017
- Summary Review of Clinical and Economic Data on H.P. Acthar® Gel (Repository Corticotropin Injection) Published in Advances in Therapy Jul 31, 2017
- Mallinckrodt Will Respond to Sen. McCaskill's Request for Information on Opioid Anti-Diversion and Suspicious Order Monitoring Activities Jul 27, 2017
- Mallinckrodt Posts Data From Legacy H.P. Acthar® Gel (Repository Corticotropin Injection) Pilot Study To clinicaltrials.gov Jul 25, 2017
- U.S. FDA Designates Mallinckrodt's StrataGraft® as Regenerative Medicine Advanced Therapy Jul 18, 2017
- Mallinckrodt Commends Governor On Ordering Prescription Drug Monitoring Program In Missouri Jul 17, 2017
- Mallinckrodt Confirms License Transfer of Synacthen® Depot; Continues Development Efforts for MNK-1411 in Treatment of DMD Jul 16, 2017
- Mallinckrodt Phase 3 Terlipressin Trial Achieves its Enrollment Target Ahead of Schedule Jul 13, 2017
- FDA Grants Orphan Drug Designation to Mallinckrodt Development Product for Potential Treatment of Duchenne Muscular Dystrophy Jul 12, 2017
- Mallinckrodt Finalizes Previously Announced Agreement with DEA and USAOs Jul 11, 2017
- Mallinckrodt Announces Specialty Brands Investor Briefing Jul 05, 2017
- Mallinckrodt plc To Report Earnings Results for Second Quarter of Fiscal 2017 Jun 29, 2017
- MNK H.P. Acthar Gel DN Trial Results Alert Jun 26, 2017
- Health Economic Data on Burden of Hepatorenal Syndrome Published in Current Medical Research and Opinion Jun 23, 2017
- Mallinckrodt Statement on H.P. Acthar® Gel (Repository Corticotropin Injection) Update Jun 22, 2017
- Mallinckrodt and Massachusetts Health & Hospital Association Announce Joint Initiative for Developing Pain Stewardship Programs Within Hospitals Jun 21, 2017
- Mallinckrodt Reinforces Facts in Response to Business Insider “Editorial” Jun 19, 2017
- Mallinckrodt Enrolls First Patient in Phase 2B Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Amyotrophic Lateral Sclerosis (ALS) Jun 14, 2017
- MNK Response to Senator McCaskill Letter Jun 08, 2017
- Mallinckrodt Enrolls First Patient in Phase 3 Trial of StrataGraft® Regenerative Skin Tissue Jun 07, 2017
- Mallinckrodt Updates Facts Refuting Short-Seller Claims Jun 06, 2017
- Mallinckrodt Statement on Sen. Mccaskill Inquiry Related to Ofirmev® (Acetaminophen) Injection May 26, 2017
- Mallinckrodt Highlights First Patients in Company-Sponsored Prospective Observational Registry on the Use of H.P. Acthar® Gel (Repository Corticotropin Injection) Following Acute Multiple Sclerosis Relapse May 25, 2017
- First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Multiple Sclerosis Relapse May 23, 2017
- Mallinckrodt Presents Facts to Refute Short-Seller Claims May 19, 2017
- Mallinckrodt Donates £100,000 to Ashford and St. Peter’s Hospitals NHS Foundation Trust to Support Neonatal Care May 19, 2017
- Mallinckrodt Opens New Global Centre for Medical Device R&D May 15, 2017
- Mallinckrodt To Present At Goldman Sachs 38th Annual Global Healthcare Conference May 12, 2017
- Mallinckrodt plc Reports Earnings Results for First Quarter of Fiscal 2017 May 08, 2017
- First Patient Enrolled in Mallinckrodt Phase 2 Trial of StrataGraft® Regenerative Skin Tissue May 04, 2017
- Mallinckrodt Celebrates 30th Anniversary of THERAKOS® Photopheresis Therapy May 03, 2017
- Mallinckrodt Data from New Company-Sponsored Studies Presented at American Academy of Neurology 69th Annual Meeting Apr 28, 2017
- Mallinckrodt To Present At UBS Global Healthcare Conference Apr 24, 2017
- Mallinckrodt Statement on H.P. Acthar® Gel (Repository Corticotropin Injection) Apr 20, 2017
- Mallinckrodt To Present At Deutsche Bank 42nd Annual Healthcare Conference Apr 05, 2017
- Mallinckrodt Statement on DEA and USAOs Agreement in Principle Apr 03, 2017
- Mallinckrodt plc To Report Earnings Results For First Quarter Of Fiscal 2017 Mar 24, 2017
- Mallinckrodt Completes Sale Of Its Intrathecal Therapy Business To Piramal Enterprises Limited For Approximately $203 Million Mar 20, 2017
- Mallinckrodt plc Board Expands Company's Share Repurchase Plan by $1.0 Billion; Company Announces Results of 2017 Annual General Meeting Mar 01, 2017
- Mallinckrodt To Present At Barclays Global Healthcare Conference Feb 24, 2017
- Mallinckrodt Statement on H.P. Acthar® Gel (Repository Corticotropin Injection) Feb 22, 2017
- Updated Mallinckrodt Statement on Extended-Release Methylphenidate Tablets Feb 21, 2017
- Mallinckrodt plc Reports Transition Period Results and Announces 2017 Guidance Feb 07, 2017
- Mallinckrodt To Sell Intrathecal Therapy Business To Piramal Enterprises Limited For Approximately $203 Million Jan 30, 2017
- Mallinckrodt Completes Sale Of Its Nuclear Imaging Business To IBA Molecular For Approximately $690 Million Jan 27, 2017
- Mallinckrodt To Present At Leerink Partners 6th Annual Global Healthcare Conference Jan 26, 2017
- Mallinckrodt And Federal Trade Commission Resolve Questcor Matter Jan 18, 2017
- Mallinckrodt Responds to Media Reports Regarding Previously Disclosed FTC Investigation Jan 18, 2017
- Karen Sheehy to Succeed Raymond Furey as Chief Compliance Officer of Mallinckrodt Jan 04, 2017
- Mallinckrodt plc To Report Earnings Results For Transition Period Of Oct. 1, 2016, To Dec. 30, 2016, On Feb. 7, 2017 Dec 29, 2016
- Mallinckrodt To Present At J.P. Morgan 35th Annual Healthcare Conference Dec 15, 2016
- Health Economic Data on OFIRMEV® (Acetaminophen) Injection Presented at 28th Annual National Forum of the Institute for Healthcare Improvement Dec 07, 2016
- Mallinckrodt Pharmaceuticals Earns Top Marks In 2017 Corporate Equality Index Dec 05, 2016
- Mallinckrodt To Present At BMO Capital Markets 2016 Prescriptions For Success Healthcare Conference Nov 30, 2016
- Mallinckrodt plc Reports Fiscal 2016 Fourth Quarter and Full-Year Results Nov 29, 2016
- Mallinckrodt Updated Statement on Extended-Release Methylphenidate Tablets Nov 23, 2016
- Mallinckrodt Will Initiate Company-Sponsored Clinical Trial of H.P. Acthar® Gel in Treatment of Amyotropic Lateral Sclerosis (ALS) Nov 21, 2016
- Clinical Pharmacokinetic and Health Economic Data on OFIRMEV® (Acetaminophen) Injection Presented at 15th Annual Pain Medicine Meeting of ASRA Nov 18, 2016
- Study Addresses Possible Impact of H.P. Acthar® Gel on Use of Corticosteroids Among Patients with Rheumatoid Arthritis, Lupus, and Dermatomyositis/Polymyositis Nov 17, 2016
- Mallinckrodt Statement on Extended-Release Methylphenidate Tablets Nov 16, 2016
- Clinical Data Analysis on Terlipressin Presented at The Liver Meeting® Nov 16, 2016
- First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel for Lupus Nov 14, 2016
- First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel for Rheumatoid Arthritis Nov 14, 2016
- Mallinckrodt Announces U.S. FDA Approval of OFIRMEV® IV Bag Presentation Nov 08, 2016
- Mallinckrodt Statement on U.S. Department of Justice Generics Industry Investigation Nov 07, 2016
- Mallinckrodt To Present At 28th Annual Piper Jaffray Healthcare Conference Nov 02, 2016
- Mallinckrodt Builds UK Presence with New Global Corporate Headquarters in Staines-upon-Thames Oct 28, 2016
- Mallinckrodt to present at Jefferies 2016 London Healthcare Conference Oct 26, 2016
- Mallinckrodt Pharmaceuticals Donates Drug Deactivation Pouches to Enable Safe Disposal of Prescription Drugs in West Virginia Oct 25, 2016
- Mallinckrodt Pharmaceuticals Donates Drug Deactivation Pouches to Enable Safe Disposal of Prescription Drugs in Kentucky Oct 20, 2016
- Mallinckrodt plc To Report Fourth Quarter And Full-Year Fiscal 2016 Results Nov. 29, 2016 Oct 18, 2016
- Children's National Health System Granted $3 Million in Research Funding by Mallinckrodt Pharmaceuticals Oct 13, 2016
- Validity of Mallinckrodt's INOMAX® Patent Claims Upheld Sep 23, 2016
- Mallinckrodt Grows Investment in Dublin College Business and Technology Park Site to €85 million Sep 19, 2016
- Mallinckrodt Completes Acquisition Of Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute Products Sep 17, 2016
- Health Economic Data Following Orthopedic Surgery for OFIRMEV® (Acetaminophen) Injection Published in Advances in Therapy Sep 01, 2016
- Mallinckrodt Completes Acquisition Of Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute Products Aug 31, 2016
- Mallinckrodt Receives FDA Fast-Track Designation for Synacthen® Depot IND Application Aug 25, 2016
- Mallinckrodt Enters Agreement To Sell Its Nuclear Imaging Business To IBA Molecular For Approximately $690 Million Aug 24, 2016
- Extracorporeal Photopheresis (ECP), Including Mallinckrodt's THERAKOS® ECP Immunomodulation, Receives Approval for Reimbursement by Swiss Federal Department of Home Affairs Aug 23, 2016
- Mallinckrodt To Present At Morgan Stanley Global Healthcare Conference Aug 22, 2016
- Mallinckrodt To Present At Wells Fargo Securities Healthcare Conference Aug 19, 2016
- Mallinckrodt Locates Growing Specialty Brands Businesses In Bedminster, N.J.; Continues Significant St. Louis Reinvestment Aug 18, 2016
- Mallinckrodt To Acquire Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute Products Aug 10, 2016
- Mallinckrodt plc Reports Fiscal 2016 Third Quarter Results and Provides Guidance for Calendar Year 2016 Aug 02, 2016
- First Patient Enrolled in Mallinckrodt Phase 3 Terlipressin Trial Jul 28, 2016
- Health Care Resource Use and Costs of H.P. Acthar® Gel (Repository Corticotropin Injection) for Multiple Sclerosis Relapse Jul 05, 2016
- Mallinckrodt plc To Report Third Quarter Fiscal 2016 Results On Aug. 2, 2016 Jun 21, 2016
- H.P. Acthar® Gel (Repository Corticotropin Injection) Health Economic Data Presented at the American Society of Health-System Pharmacists Summer Meetings Jun 20, 2016
- Mallinckrodt Donates One Million Drug Deactivation Pouches To Support U.S. Fight Against Prescription Drug Abuse Jun 16, 2016
- Mallinckrodt Submits Investigational New Drug Application for Synacthen® Depot Jun 13, 2016
- Mallinckrodt Presents New Data from 44-Week Open Label Extension Of Company-Sponsored H.P. Acthar® Gel Trial in Lupus Jun 09, 2016
- Mallinckrodt Donates 250,000 Drug Deactivation Systems to ACT Missouri to Support Fight Against Prescription Drug Abuse May 23, 2016
- Mallinckrodt Grows Investment in Dublin College Business and Technology Park Site to €85 million May 19, 2016
- Mallinckrodt plc to Change Fiscal Year May 18, 2016
- First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel for Rare Cause of Nephrotic Syndrome May 17, 2016
- Mallinckrodt plc Reports Fiscal 2016 Second Quarter Results May 03, 2016
- Mallinckrodt to Present at UBS Global Healthcare Conference Apr 27, 2016
- H.P. Acthar® Gel (Repository Corticotropin Injection) Health Economic Data Presented at the Academy of Managed Care Pharmacy’s (AMCP) Annual Meeting Apr 26, 2016
- OFIRMEV® (Acetaminophen) Injection Health Economic Data Presented and Specially Recognized at Annual Congress of Enhanced Recovery and Perioperative Medicine Apr 25, 2016
- OFIRMEV® (Acetaminophen) Injection Health Economic Data Presented at Women’s Health 2016: The 24th Annual Congress Apr 18, 2016
- Mallinckrodt To Present At Bank Of America Merrill Lynch 2016 Healthcare Conference Apr 11, 2016
- Mallinckrodt To Present At Deutsche Bank 41st Annual Healthcare Conference Apr 04, 2016
- OFIRMEV® (Acetaminophen) Injection Health Economic Data Presented at 41st Annual Regional Anesthesiology and Acute Pain Medicine Meeting Mar 31, 2016
- Mallinckrodt plc To Report Second Quarter Fiscal 2016 Results On May 3, 2016 Mar 22, 2016
- Mallinckrodt Recognizes Patient Safety Awareness Week, Endorses Multimodal Analgesia Approach to Minimize Opioid Overuse in Hospital Acute Pain Management Mar 17, 2016
- Mallinckrodt plc Announces Results of 2016 Annual General Meeting; Board Expands Company's Share Repurchase Plan by $350 million Mar 17, 2016
- Mallinckrodt Pharmaceuticals Expands Nuclear Medicine Offerings, Announces U.S. Availability of Xenon 133 Mar 10, 2016
- Mallinckrodt CEO Mark Trudeau Urges Support for Missouri Prescription Drug Monitoring Measure to Fight Prescription Drug Abuse Feb 29, 2016
- Mallinckrodt plc Reports Fiscal 2016 First Quarter Results Feb 02, 2016
- Mallinckrodt Completes Acquisition Of Three Commercial-Stage, Global Specialty Hemostasis Brands From The Medicines Company Feb 01, 2016
- Mallinckrodt To Present At Leerink Partners Global Healthcare Conference Jan 28, 2016
- Mallinckrodt plc To Report First Quarter Fiscal 2016 Results On Feb. 2, 2016 Jan 12, 2016
- Mallinckrodt Diversifies Hospital Growth Portfolio, Acquiring Three Commercial-Stage, Global Specialty Hemostasis Brands From The Medicines Company Dec 18, 2015
- Mallinckrodt CEO Mark Trudeau Nominated To TE Connectivity Board Of Directors Dec 17, 2015
- Mallinckrodt To Present At J.P. Morgan 34th Annual Healthcare Conference Dec 15, 2015
- Mallinckrodt plc Discusses R&D Initiatives, Company Outlook at Investor Briefing Dec 07, 2015
- Mallinckrodt Completes Sale Of Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million Nov 27, 2015
- Mallinckrodt plc Reports Financial Results For Fiscal 2015 Fourth Quarter and Full Year Nov 23, 2015
- Mallinckrodt plc Board Adds $500 Million To Company's Existing Share Repurchase Program Nov 19, 2015
- Mallinckrodt Provides Synacthen® Depot and Synacthen Update Nov 17, 2015
- Mallinckrodt Pharmaceuticals Receives FDA Clearance For INOmax DS(IR)® Plus MRI Device Nov 16, 2015
- Mallinckrodt to Present at Oppenheimer 26th Annual Healthcare Conference Nov 10, 2015
- Mallinckrodt Study Shows Acthar® Reduces Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus Nov 09, 2015
- Mallinckrodt To Present At Piper Jaffray 27th Annual Healthcare Conference Nov 04, 2015
- Mallinckrodt's INOmax® Approved In Australia And Japan For Pulmonary Hypertension In Conjunction With Heart Surgery Oct 30, 2015
- Mallinckrodt plc to Report Fourth Quarter and Full-Year Fiscal 2015 Results Nov. 23, 2015; Investor Briefing Planned on Dec. 7, 2015 Oct 26, 2015
- Mallinckrodt Statement on 1940s-1950s U.S. Government Contract Work Oct 14, 2015
- Clinical Data on Mallinckrodt Pharmaceuticals' H.P. Acthar® Gel to be Unveiled at American College of Rheumatology Oct 13, 2015
- Mallinckrodt plc Provides Business Update Including Fiscal Year 2016 Financial Guidance Excluding Contrast Media and Delivery Systems (CMDS) and Ex-CMDS Historical Financial Information Oct 06, 2015
- Mallinckrodt Announces Clinical and Healthcare Economics Research Study Data Presented and Published in Fourth Quarter Fiscal 2015 Oct 06, 2015
- Mallinckrodt plc to Provide Business Update, Fiscal Year 2016 Financial Guidance and Historical Financial Information Excluding Contrast Media and Delivery Systems (CMDS) Oct 05, 2015
- Mallinckrodt Completes Acquisition Of Therakos, Inc. Sep 28, 2015
- Mallinckrodt Launches Notes Offering Sep 09, 2015
- Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Acquisition Of Therakos, Inc. Aug 10, 2015
- Mallinckrodt plc Reports Fiscal 2015 Third Quarter Financial Results Aug 04, 2015
- Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million Jul 27, 2015
- Mallinckrodt plc To Report Third Quarter Fiscal 2015 Results On August 4, 2015 Jul 07, 2015
- Mallinckrodt To Present At Goldman Sachs 36th Annual Healthcare Conference May 27, 2015
- Mallinckrodt Extends Deadline For 2015 Research Fellowship Program May 26, 2015
- Mallinckrodt plc announces €45m Investment in Ireland May 20, 2015
- Mallinckrodt plc announces €45m Investment in Ireland May 20, 2015
- Mallinckrodt plc Reports Fiscal 2015 Second Quarter Financial Results; Raises Full Year 2015 Guidance May 05, 2015
- Mallinckrodt To Present At Bank Of America Merrill Lynch 2015 Health Care Conference May 04, 2015
- Mallinckrodt To Present At Deutsche Bank Healthcare Conference Apr 22, 2015
- Mallinckrodt Completes Acquisition Of Ikaria Apr 16, 2015
- Mallinckrodt Statement On Agreement To Settle Questcor Shareholder Lawsuit Apr 13, 2015
- Mallinckrodt plc to Report Second Quarter Fiscal 2015 Results on May 5, 2015 Apr 07, 2015
- Mallinckrodt Launches Notes Offering Apr 06, 2015
- Positive Outcomes With H.P. Acthar® Gel In Proteinuria In Nephrotic Syndrome Reported At National Kidney Foundation Spring Congress Mar 27, 2015
- Mallinckrodt Receives Favorable Decision in Ofirmev (Acetaminophen) Injection Patent Case Mar 24, 2015
- Mallinckrodt Supports Safe Home Disposal Of Unused Medications Mar 09, 2015
- Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition Mar 05, 2015
- Mallinckrodt to Present at Barclays Conference March 11 Mar 04, 2015
- Mallinckrodt plc Reports Fiscal 2015 First Quarter Financial Results Feb 03, 2015
- Mallinckrodt plc Announces Share Repurchase Program Jan 23, 2015
- Mallinckrodt Builds Leadership To Support Continued Growth Jan 07, 2015
- Mallinckrodt plc to Report First Quarter Fiscal 2015 Results on February 3, 2015 Jan 05, 2015
- Mallinckrodt to Present at J.P. Morgan Healthcare Conference January 12 Dec 22, 2014
- Mallinckrodt to Present at Piper Jaffray 26th Annual Healthcare Conference in New York Dec 01, 2014
- Mallinckrodt Responds to Court Decision Nov 25, 2014
- Mallinckrodt plc Reports Fiscal 2014 Fourth Quarter and Fiscal 2014 Financial Results Nov 19, 2014
- Mallinckrodt Responds to FDA Reclassification Of Methylphenidate ER Nov 19, 2014
- Mallinckrodt plc Responds to FDA’s Expected Reclassification of Methylphenidate ER Nov 13, 2014
- Mallinckrodt plc to Report Fourth Quarter and Full-Year Fiscal 2014 Results on November 19, 2014 Oct 20, 2014
- Mallinckrodt plc Provides Fiscal Year 2015 Financial Guidance Oct 14, 2014
- Mallinckrodt Pharmaceuticals Announces U.S. Launch Of OptiSync™ Data Management System Sep 22, 2014
- New REMS Education Program Helps Increase Safe, Responsible Use of Opioid Analgesics for Pain Relief Sep 08, 2014
- Mallinckrodt Pharmaceuticals Presents 11 Posters with Data on Investigational Opioid, MNK-155, and XARTEMIS™ XR (oxycodone hydrochloride and acetaminophen) Extended Release Tablets (CII) at PAINWeek 2014 Sep 05, 2014
- Mallinckrodt Pharmaceutical’s MNK-155, an Extended-Release Hydrocodone/Acetaminophen Combination, Shows Efficacy in Phase 3 Acute Pain Trial Sep 04, 2014
- Mallinckrodt Pharmaceuticals Releases Human Abuse Liability (HAL) Data for Investigational MNK-155, an Extended-Release Hydrocodone/Acetaminophen Combination Sep 03, 2014
- Mallinckrodt Pharmaceuticals to Hold Investor Briefing October 14, 2014, in New York Sep 02, 2014
- Mallinckrodt Pharmaceuticals to Present Data for Investigational and Approved Extended-Release Opioid Combination Medicines at PAINWeek Aug 28, 2014
- Mallinckrodt to Present at Morgan Stanley 2014 Global Healthcare Conference Aug 25, 2014
- Mallinckrodt Announces Key Leadership Appointments Following Completion of Questcor Acquisition Aug 22, 2014
- Mallinckrodt Now a Component of the S&P 500 Index Aug 19, 2014
- Mallinckrodt Completes Acquisition Of Questcor Pharmaceuticals Aug 14, 2014
- Mallinckrodt And Questcor Shareholders Approve Mallinckrodt's Acquisition Of Questcor Aug 14, 2014
- Mallinckrodt plc Reports Fiscal 2014 Third Quarter Financial Results; Updates Full-Year 2014 Guidance, Increasing Net Sales and Adjusted Diluted Earnings Per Share Aug 07, 2014
- Mallinckrodt Pharmaceuticals Announces Settlement of OFIRMEV® (acetaminophen) Injection Patent Litigation with Fresenius Kabi USA, LLC Aug 06, 2014
- Mallinckrodt Receives Patent from U.S. Patent and Trademark Office Aug 06, 2014
- Institutional Shareholder Services Inc. And Glass Lewis Recommend That Shareholders Of Mallinckrodt And Questcor Vote FOR Mallinckrodt's Acquisition Of Questcor Aug 04, 2014
- New Public Television Special Facilitates National Pain Management Dialogue Jul 29, 2014
- Questcor Reports Record Second Quarter Financial Results Jul 24, 2014
- Mallinckrodt plc to Report Third Quarter Results on August 7, 2014 Jul 14, 2014
- Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction Jul 14, 2014
- Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction Jul 14, 2014
- Mallinckrodt Pharmaceuticals Names Mark Tyndall Vice President, Government Affairs Jul 07, 2014
- Questcor Pharmaceuticals Closes Transaction to Acquire International Rights to Synacthen® and Synacthen® Depot Jun 23, 2014
- Mallinckrodt to Present at Goldman Sachs 2014 Global Healthcare Conference Jun 04, 2014
- Questcor Provides Support to Lupus Foundation of America Awareness, Education and Advocacy Efforts Jun 03, 2014
- Mallinckrodt to Present at Jefferies 2014 Global Healthcare Conference May 30, 2014
- Questcor Receives "Recognition of Appreciation" Award from MS Views & News May 28, 2014
- Mallinckrodt Pharmaceuticals’ New Drug Application Accepted for Review by FDA May 28, 2014
- Questcor Enters Into Development Collaboration Agreement Covering Novel Receptor-Selective Melanocortin Peptides May 14, 2014
- Mallinckrodt Pharmaceuticals and Questcor Pharmaceuticals Announce Early Termination of HSR Act Waiting Period May 12, 2014
- Mallinckrodt Pharmaceuticals and Questcor Pharmaceuticals Announce Early Termination of HSR Act Waiting Period May 12, 2014
- Mallinckrodt plc Reports Fiscal 2014 Second Quarter Financial Results; Increases Full-Year 2014 Guidance May 08, 2014
- Cinical Trial Results Indicate Acthar May Significantly Reduce Disease Activity in Patients with Systemic Lupus Erythematosus May 05, 2014
- Mallinckrodt Pharmaceuticals to Present New Clinical Data at American Pain Society Annual Scientific Meeting Apr 30, 2014
- Questcor Reports First Quarter Financial Results Apr 28, 2014
- Questcor to Report First Quarter Financial Results on April 28, 2014 Apr 24, 2014
- Clinical Trial Results Indicate Acthar May Significantly Reduce Proteinuria in Patients with Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy Apr 21, 2014
- Mallinckrodt plc to Report Second Quarter Results on May 8, 2014 Apr 21, 2014
- Questcor Partners with National Kidney Foundation as National Sponsor of Kidney Walk Apr 17, 2014
- Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Enter Into Definitive Merger Agreement Under Which Mallinckrodt Will Acquire Questcor For Approximately $5.6 Billion, Creating A Diversified, High-Growth Specialty Pharmaceuticals Company Apr 07, 2014
- Questcor Announces Quarterly Cash Dividend Apr 07, 2014
- Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Enter Into Definitive Merger Agreement Under Which Mallinckrodt Will Acquire Questcor For Approximately $5.6 Billion, Creating A Diversified, High-Growth Specialty Pharmaceuticals Company Apr 07, 2014
- Mallinckrodt Pharmaceuticals and Verde Environmental Technologies, Inc., Team to Provide Medsaway Medication Disposal System Apr 03, 2014
- Questcor Contributes $175,000 to Endowment of Philip R. Dodge Young Investigator Award for Pediatric Neurology Mar 20, 2014
- Mallinckrodt plc Completes $1.4 Billion Acquisition of Cadence Pharmaceuticals, Inc. Mar 19, 2014
- Mallinckrodt plc Receives FDA Approval For XARTEMIS XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII) Mar 12, 2014
- Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results Feb 28, 2014
- Mallinckrodt to Present at Barclays Global Healthcare Conference Feb 27, 2014
- Questcor Reports Fourth Quarter and Full Year 2013 Financial Results Feb 25, 2014
- Mallinckrodt Receives Patent from U.S. Patent and Trademark Office Feb 25, 2014
- Questcor Announces Quarterly Cash Dividend Feb 14, 2014
- Questcor to Report Fourth Quarter and Full Year 2013 Financial Results on February 25, 2014 Feb 12, 2014
- Mallinckrodt plc to Acquire Cadence Pharmaceuticals, Inc. for $14.00 Per Share, in Cash Feb 11, 2014
- Mallinckrodt plc to Acquire Cadence Pharmaceuticals, Inc. for $14.00 Per Share, in Cash Feb 11, 2014
- Mallinckrodt Pharmaceuticals’ New Drug Available to Patients Feb 10, 2014
- Mallinckrodt plc Reports Fiscal 2014 First Quarter Financial Results And Revises Full-Year Guidance Feb 06, 2014
- Questcor Pharmaceuticals Expands Senior Management Team Feb 05, 2014
- Mallinckrodt to Present at Leerink Swann Global Healthcare Conference Feb 05, 2014
- Mallinckrodt plc Announces Winners in Dublin Science Week Competition Jan 31, 2014
- Questcor Commits $500,000 to Launch of Questcor Research Fellowship Program for 2014 Jan 22, 2014
- Mallinckrodt Pharmaceuticals New Drug Application Approved by the FDA Jan 17, 2014
- Cadence Pharmaceuticals Estimates Fourth Quarter and Full Year 2013 Product Revenue and Provides Full Year 2014 Revenue Guidance Jan 13, 2014
- Mallinckrodt Pharmaceuticals Announces Clinical And Commercial Collaboration With Medtronic Jan 13, 2014
- Mallinckrodt Pharmaceuticals and Zogenix to End Co-Promotion Agreement Jan 09, 2014
- Questcor Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference Jan 08, 2014
- Mallinckrodt plc to Report First Quarter Results on Thursday, February 6, 2014 Jan 07, 2014
- Mallinckrodt to Present at J.P. Morgan Healthcare Conference Jan 02, 2014
- Questcor Provides Donation In Support Of Children's Hospital & Research Center Oakland Dec 17, 2013
- Mallinckrodt Pharmaceuticals Announces Completion of MNK-155 Clinical Trials Dec 12, 2013
- Questcor Announces Quarterly Cash Dividend and Provides Update on Share Repurchase Program Dec 11, 2013
- New Data Detailing Economic Impact of IV Acetaminophen in Treating Acute Pain to be Presented at Two Major Healthcare Conferences Dec 09, 2013
- Questcor and Child Neurology Foundation Support the 5th Annual Infantile Spasms Awareness Week Dec 09, 2013
- Questcor Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference Dec 05, 2013
- Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The 25th Annual Piper Jaffray Healthcare Conference On December 4, 2013 Nov 26, 2013
- Mallinckrodt to Present at the 25th Annual Piper Jaffray Healthcare Conference in New York Nov 25, 2013
- U.S. Food and Drug Administration (FDA) Extends Review of Mallinckrodt’s New Drug Application for XARTEMIS™ XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII) Nov 25, 2013
- Questcor Honored as an "Everyday Hero" by NephCure Foundation Nov 22, 2013
- Mallinckrodt plc Announces Annual Shareholder Meeting Date Nov 21, 2013
- Cadence Pharmaceuticals Reports Positive Outcome In OFIRMEV® Patent Litigation Nov 14, 2013
- Mallinckrodt to Present at Jefferies 2013 Global Healthcare Conference in London Nov 13, 2013
- Questcor Adds G. Kelly Martin to Board of Directors Nov 12, 2013
- Cadence Pharmaceuticals Recognized As A Top Workplace In San Diego Based On Employee Feedback Nov 08, 2013
- CORRECTING and REPLACING Mallinckrodt Pharmaceuticals to Hold Investor Briefing in New York Nov 08, 2013
- Mallinckrodt Pharmaceuticals to Hold Investor Briefing in New York Nov 08, 2013
- Questcor Pharmaceuticals to Present at the 2013 Credit Suisse Annual Healthcare Conference Nov 07, 2013
- Mallinckrodt plc Reports Fourth-Quarter and Fiscal 2013 Financial Results Nov 07, 2013
- Mallinckrodt Pharmaceuticals and Pharmachemical Ireland Announce 2013 Science Week Competition Nov 06, 2013
- Mallinckrodt plc Celebrates 20 Years of Successful Operations in Ireland Nov 06, 2013
- Mallinckrodt Pharmaceuticals Receives Conditional Approval of Proprietary Name XARTEMIS™ XR for MNK-795 Nov 05, 2013
- Cadence Pharmaceuticals Reports Third Quarter 2013 Financial Results Nov 05, 2013
- Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2013 Financial Results On November 5, 2013 Oct 29, 2013
- Questcor Reports Third Quarter Financial Results Oct 29, 2013
- Mallinckrodt Pharmaceuticals Announces Executive Appointments Oct 24, 2013
- Questcor To Commence Phase 2 Study of Acthar for Acute Respiratory Distress Syndrome Oct 22, 2013
- Mallinckrodt Pharmaceuticals Provides Financial Outlook for Fiscal Year 2014 Oct 16, 2013
- Questcor Increases Quarterly Cash Dividend 20 Percent Oct 10, 2013
- Mallinckrodt Pharmaceuticals Extends Patent Coverage for Octreoscan™ (Kit for the Preparation of Indium In-111 Pentetreotide) Oct 09, 2013
- Questcor to Report Third Quarter Financial Results on October 29, 2013 Oct 08, 2013
- Mallinckrodt plc to Report Fourth Quarter Results on November 7, 2013 Oct 07, 2013
- Mallinckrodt to Provide Fiscal 2014 Guidance Oct 02, 2013
- Mallinckrodt Pharmaceuticals Presented 15 Posters on Investigational Drug at PAINWeek 2013 Sep 06, 2013
- Questcor Pharmaceuticals to Participate in Morgan Stanley Global Healthcare Conference Sep 05, 2013
- Mallinckrodt Pharmaceuticals Announces Positive Phase 3 Efficacy Results for MNK-795, an Extended-Release Oxycodone/Acetaminophen Combination Sep 05, 2013
- Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2013 On September 11, 2013 Sep 04, 2013
- Mallinckrodt Pharmaceuticals Reports Human Abuse Liability (HAL) Data for MNK-795, an Extended-Release Oxycodone/Acetaminophen Combination Sep 04, 2013
- Mallinckrodt Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference Sep 03, 2013
- Mallinckrodt Pharmaceuticals Continues Efforts to Fight Medicine Abuse with The Partnership® at Drugfree.org Sep 03, 2013
- Mallinckrodt Pharmaceuticals to Unveil First Clinical Data on MNK-795, an Extended-Release Oxycodone and Acetaminophen Combination, at PAINWeek Aug 28, 2013
- Questcor Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference Aug 27, 2013
- Mallinckrodt Pharmaceuticals’ New Drug Application Accepted for Review by FDA Aug 22, 2013
- Mallinckrodt Pharmaceuticals Signs Distribution Agreement with Amneal Pharmaceuticals LLC Aug 20, 2013
- Cadence Pharmaceuticals Appoints Laureen DeBuono to its Board of Directors Aug 15, 2013
- Cadence Pharmaceuticals Comments on USPTO's Non-Final, Initial Office Action on Reexamination of Patent Aug 15, 2013
- Mallinckrodt plc Reports Financial Results for Third Fiscal Quarter 2013 Aug 09, 2013
- Cadence Pharmaceuticals To Present At The 2013 Wedbush PacGrow Life Sciences Management Access Conference On August 13, 2013 Aug 06, 2013
- Cadence Pharmaceuticals Reports Second Quarter 2013 Financial Results Jul 31, 2013
- Questcor Reports Second Quarter Financial Results Jul 30, 2013
- Mallinckrodt New Drug Application Granted Priority Review by FDA Jul 29, 2013
- Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Second Quarter 2013 Financial Results On July 31, 2013 Jul 24, 2013
- Questcor to Commence Phase 2 Study of Acthar for ALS Jul 24, 2013
- Questcor to Report Second Quarter Financial Results on July 30, 2013 Jul 12, 2013
- Questcor to Initiate Pilot Commercialization Effort In Pulmonology for Symptomatic Sarcoidosis Jul 11, 2013
- Mallinckrodt plc to Report Third Quarter Results on August 9, 2013 Jul 09, 2013
- Cadence Pharmaceuticals To Present At The 8th Annual JMP Securities Healthcare Conference On July 9, 2013 Jul 02, 2013
- Mallinckrodt plc Begins Trading on New York Stock Exchange Jul 01, 2013
- Questcor Pharmaceuticals Acquires Rights to Synacthen® Jun 11, 2013
- Questcor Adds Angus C. Russell to Board of Directors Jun 10, 2013
- Questcor Pharmaceuticals Announces Quarterly Dividend May 29, 2013
- Questcor Pharmaceuticals to Present at Bank of America Merrill Lynch 2013 Healthcare Conference May 08, 2013
- Cadence Pharmaceuticals To Present At Three Investment Conferences During The Month Of May 2013 May 08, 2013
- Covidien Announces First Full-Year Outlook for Mallinckrodt plc May 03, 2013
- Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results May 02, 2013
- Questcor Reports First Quarter Financial Results Apr 30, 2013
- Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss First Quarter 2013 Financial Results On May 2, 2013 Apr 25, 2013
- Questcor to Report First Quarter Results on April 30, 2013 Apr 15, 2013
- Cadence Pharmaceuticals Appoints Stephen L. Newman, M.D., to its Board of Directors Mar 14, 2013
- Cadence Pharmaceuticals Announces the Availability of OFIRMEV® (acetaminophen) Injection through the VA National Formulary Mar 12, 2013
- Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results Mar 07, 2013
- Cadence Pharmaceuticals Announces Strategic Plan to Secure Long-Term Manufacture and Supply of OFIRMEV® (acetaminophen) Injection Mar 06, 2013
- Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2012 Financial Results On March 7, 2013 Feb 28, 2013
- Questcor Reports Fourth Quarter and Full Year 2012 Results Feb 26, 2013
- Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013 Feb 26, 2013
- Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013 Feb 06, 2013
- Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The Leerink Swann Global Healthcare Conference In New York City On February 13, 2013 Feb 06, 2013
- Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development Jan 28, 2013
- Cadence Pharmaceuticals Estimates Fourth Quarter 2012 Net Product Revenue and Provides Full Year 2013 Revenue Guidance Jan 23, 2013
- Questcor Pharmaceuticals to Present at J.P. Morgan Healthcare Conference Jan 03, 2013
- Questcor Pharmaceuticals to Acquire BioVectra Inc. Jan 02, 2013
- Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc. Dec 12, 2012
- Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012 Dec 04, 2012
- Questcor Teams With Child Neurology Foundation To Continue Funding Infantile Spasms Scientific Research Dec 03, 2012
Our Commitment
To providing safe and effective medications for the treatment of patients in pain.
Responsible UseOur Culture
From philanthropic efforts to advocacy initiatives, we are living our values throughout our communities.
Learn How